Please assess the completion status of the following clinical trial:

Trial Title: Clinical Effects and Safety of 3% Diquafosol After Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bilateral or unilateral cataract undergoing phacoemulsification and intraocular lens (IOL) implantation at Soonchunhyang University Hospital between January 2014 and January 2015~* Patients with mild to moderate dry eye (level 1 or 2) based on the dry eye severity scale adopted by the Dry Eye Workshop (DEWS) report and who used only artificial tears occasionally~Exclusion Criteria:~* Presence of any complications after cataract surgery such as cystoid macular edema~* Patients using any topical eye drops on a regular basis~* Treatment history of dry eye beyond artificial tears~* Any ocular surgery within the prior 6 months~* Contact lens wear~* Serious ocular surface disease (e.g., Sjögren's syndrome, ocular pemphigoid, conjunctival scarring, chemical injury)~* Eyelid or lacrimal disease~* Use of concomitant medications that could cause dry eye and allergy to any of the study medications

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Diqufosol (Type: ACTIVE_COMPARATOR): 3% Diquafosol Tetrasodium Ophthalmic Solution
- Hyaluronate (Type: PLACEBO_COMPARATOR): 0.1% Sodium Hyaluronate Ophthalmic Solution

Based on this trial design, predict the completion outcome and termination type (if applicable).